BiotechTube
Xlife Sciences

Xlife Sciences

XLS.SW
Zurich, Switzerland· Est.
xlifesciences.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

XLS.SW · Stock Price

CHF 21.10+0.10 (+0.48%)
Market Cap: $158.0M

Historical price data

Market Cap: $158.0MFounded: 2019HQ: Zurich, Switzerland

Overview

Xlife Sciences AG operates a unique value-creation platform model, identifying and de-risking early-stage life science innovations from academic origins. Its strategy involves forming dedicated project companies, providing capital and operational support to achieve pre-clinical proof-of-concept, and targeting exits within 2-3 years via trade sales or licensing. Recent achievements include the announced exit of 12 project companies to Grupo Landsteiner and progress toward a NASDAQ listing for its portfolio company VERAXA Biotech, highlighting its execution on the value inflection strategy.

OncologyNeurologyVarious

Technology Platform

A systematic value-creation and project acceleration platform focused on sourcing early-stage academic innovations, forming dedicated project companies, providing active operational management, and driving them to pre-clinical proof-of-concept for strategic exit.

Funding History

1
Total raised:$50M
IPO$50M

Opportunities

The company is positioned to capitalize on the growing trend of pharma outsourcing early-stage innovation and the increasing value of platform technologies in digital health and AI.
Successful execution of its exit-driven model could generate significant capital gains and establish a repeatable funding cycle.

Risk Factors

High dependency on successful exits for returns, concentration risk in a portfolio of early-stage assets, and vulnerability to downturns in the biotech financing and M&A markets.
Operational scalability of the hands-on project management model is untested at larger scale.

Competitive Landscape

Competes with early-stage life science venture capital firms, biotech incubators, and other venture builders for high-quality academic assets. Differentiates through its integrated operational support and public market financing, but faces intense competition for breakthrough innovations.

More companies in Switzerland →